Deal round up 09/07/02

Cross Atlantic backs MobileAware; Four Seasons leads Scali round; Alta and Axa back Innate Pharma

Cross Atlantic backs MobileAware

Cross Atlantic Capital Partners, the venture capital firm with offices in Philadelphia, Dublin and London, has led a E7m second round of financing for Irish mobility solutions provider MobileAware. The latest round of financing will be used to accelerate MobileAware’s technology development and to boost the firm’s presence in the provision of mobile solutions.

Existing shareholders, including Intel Capital and Cross Capital, have increased their commitment to MobileAware. They have been joined by AIB Equity and Bank of America Capital Partners, which is making its first investment in an Irish software company.

Four Seasons leads Scali round

Scali AS has closed the second round of its Series B funding round. New investor Four Seasons Venture III led the round. Intel Capital joined as an investor and existing investors Kongsberg Gruppen and SND Invest also participated. Financial details of the fundraising total have not been disclosed.

Scali develops Linux-based software designed to enable companies to create supercomputing capabilities from standard servers. The funds will be used to strengthen the firm's technology platform, with the firm anticipating that the market for clustering solutions is set to grow significantly over the next three to five years. Current customers include Daimler Chrysler, BMW, deCode Genetics, Lockheed Martin, Norsk Hydro, US Naval Air, PGS and Rolls Royce.

Alta and Axa back Innate Pharma

French drug research company Innate Pharma has raised E20m in its second round of venture financing. The Daily Deal reports that both European and American firms have invested capital, including co-leaders Alta Partners and Axa Private Equity.

Innate Pharma has also received investment from Pechel Industries, Gilde Biotech & Nutrition and Innoveris, along with prior investors Sofinnova Partners, GIMV and Auriga. The Marseille-based firm develops treatments for tumors and cancer-related disorders.